|Autoantibody and disease features of patients with the five major autoantibodies against citrullinated protein profilesa|
|Group||n||Anti-CCP2+b (%)||RF+ (%)||Mean ACPA level (U/ml)||Mean number of citrullinated antigens recognized (range)c,d||(Ex-) smokers (%)e||SE+f (%)d||VAS mediang|
|C||15||100||93||4630||6 (1 to 16)||38||93||34|
|D||83||88||87||1317||3 (1 to 13)||59||80||35|
|E||30||87||87||861||2 (0 to 5)||66||70||34|
|F||198||31||45||137||0 (0 to 4)||49||53||40|
|H||17||0||29||14||0 (0 to 1)||60||29||50|
aACPA: anticitrullinated protein antibody; CCP2: cyclic citrullinated peptide 2; RF: rheumatoid factor; SE: shared epitope; VAS: Visual Analogue Scale score. bMeasured using the anti-CCP2 test (CCPlus Immunoscan assay). cReactivity is based upon cutoff values determined with reactivity of healthy individuals with surface plasmon resonance imaging. dP-value < 0.01. eP-value = 0.278. fAt least one SE allele. gP-value = 0.958. Group differences were tested using the Kruskal-Wallis test or Pearson’s χ2 test.
van Beers et al.
van Beers et al. Arthritis Research & Therapy 2013 15:R140 doi:10.1186/ar4322